However, most DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, alogliptin) are predominantly excreted by the kidneys, and dose reductions are needed according to the severity of CKD (Scheen, 2015). The gene discussed is DPP4; the disease is chronic kidney disease.